Continuing Education

The 25th World Congress on Gastrointestinal Cancer is accredited by the European Society for Medical Oncology to award 25 Category 1 ESMO-MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology.

Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Learning Objectives

After attending this Congress, participants should be able to:

Identify current controversies in the management of patients with gastric, gastro-esophageal junction, and esophageal cancers

Describe the use of prognostic and predictive molecular markers for gastric cancer

Describe the epidemiology and pathogenesis of hepatocellular carcinoma

Discuss management of patients with hepatocellular carcinoma

Discuss management of patients with bile duct cancer

Discuss the use of molecular markers for guiding treatment decisions in bile duct cancer

Identify neoadjuvant and adjuvant treatment options for patients with locally advanced and borderline resectable pancreatic cancer

Discuss current and new treatment options for patients with metastatic cancer of the pancreas

Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer

Describe the use of molecular markers for screening and prognosis of colorectal cancer

Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients

Comment on new agents in the treatment of colorectal cancer and the latest clinical trial results

Identify treatment strategies for early and locally advanced and metastatic rectal cancer

Distinguish between appropriate surgical techniques for the treatment of gastrointestinal, hepatobiliary, and pancreatic cancers

Understand the role of molecular markers in digestive cancers

Describe the immune mechanisms associated with gastrointestinal cancers

Understand relevant pathways and the role of new targets in GI cancer

Understand the best imaging modalities for diagnosis, staging, and response prediction in GI cancer

Understand the diagnostic and therapeutic pitfalls in rare GI cancers, including neuroendocrine tumors, GIST, and anal cancer

Discuss the endpoints of clinical trials and clinical trial methodology

Discuss the pharmacoeconomic principles involved in gastrointestinal cancers

Understand the developments of artificial intelligence in GI cancer

Understand the need to incorporate translational and clinical research to promote digestive cancers control

Continuing Education